Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886).
about
Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform NeurofibromasIdentification of an In Vivo MEK/WOX1 Complex as a Master Switch for Apoptosis in T Cell Leukemia.Dropped head syndrome: report of three cases during treatment with a MEK inhibitor.CInQ-03, a novel allosteric MEK inhibitor, suppresses cancer growth in vitro and in vivo.Synchronous BRAF(V600E) and MEK inhibition leads to superior control of murine melanoma by limiting MEK inhibitor induced skin toxicity.A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors.Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management.Cutaneous effects of BRAF inhibitor therapy: a case series.Dermatological adverse events from BRAF inhibitors: a growing problem.Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions.Risk of selected dermatological toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis.Ocular toxicities of MEK inhibitors and other targeted therapies.Selumetinib in the treatment of non-small-cell lung cancer.Cutaneous Complications of Targeted Melanoma Therapy.Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-small-cell lung cancer.Novel cutaneous effects of combination chemotherapy with BRAF and MEK inhibitors: a report of two cases.The safety and efficacy of dabrafenib and trametinib for the treatment of melanoma.[Cutaneous side effects of anti-tumor therapy with BRAF and MEK inhibitors].A mitogen-activated protein kinase kinase inhibitor induced compound skin toxicity with oedema in metastatic malignant melanoma.Systemic Drug-induced Chronic Paronychia and Periungual Pyogenic Granuloma
P2860
Q33900906-C41EBAD1-062C-46AB-A061-0B537E41C990Q35180343-5F51C3DE-B8FA-4DD6-889E-18022CE5D11FQ36475286-68AEFD06-0EB4-451F-AF7D-169CCA649A82Q36813976-4C97B03E-C426-44F3-A5B3-7CB6D3F1F594Q37360534-152B35C0-F114-4B6E-B585-7FEF7FA686E1Q37639582-23FE9760-7154-4CEC-B387-AA1B66819EE8Q38005994-D01F2F05-F023-4C03-AEF7-04BC7EE2069FQ38049306-E58ECFFF-2DCE-418F-BC37-FDE336C8AF8FQ38086762-B9D902C2-BA78-4E54-B773-F16531C6E7B6Q38123513-409D3E83-4F1F-4B1B-9554-DF0BBC1A908AQ38631710-63B5F0A0-A070-4B44-99FC-AE53235573C4Q38764273-A63BEF80-4457-4DE1-9F85-012BDD072E35Q38836927-52AD1F15-D6A4-4068-822D-DA0329046F77Q38958844-1B2FCC68-4612-476A-8D27-4F2ED899DCD2Q39466460-211D067C-C5A4-47B7-8F07-C3AF4821A254Q46887584-E521E059-BAC2-4D85-B569-379D6BCEFA69Q47549324-F042E454-73E9-4F11-A5F8-6136521696C9Q53063698-2FDFABE0-0D51-446E-A7BD-61BB2AAF73C0Q55041944-AD47910D-0187-4F28-91AE-DAAB1327C6F6Q58774943-647ACF32-A6A8-4D09-99D0-90755113C765
P2860
Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886).
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Dermatologic side effects asso ...... etinib (AZD6244, ARRY-142886).
@en
Dermatologic side effects asso ...... etinib (AZD6244, ARRY-142886).
@nl
type
label
Dermatologic side effects asso ...... etinib (AZD6244, ARRY-142886).
@en
Dermatologic side effects asso ...... etinib (AZD6244, ARRY-142886).
@nl
prefLabel
Dermatologic side effects asso ...... etinib (AZD6244, ARRY-142886).
@en
Dermatologic side effects asso ...... etinib (AZD6244, ARRY-142886).
@nl
P2093
P2860
P1476
Dermatologic side effects asso ...... etinib (AZD6244, ARRY-142886).
@en
P2093
Katherine Barth Huston
Klaus J Busam
Patricia L Myskowski
Paul B Chapman
Yevgeniy Balagula
P2860
P2888
P304
P356
10.1007/S10637-010-9567-3
P577
2010-10-27T00:00:00Z